We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 10 for:    cd101

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis (STRIVE)

This study is currently recruiting participants.
Verified October 2017 by Cidara Therapeutics Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02734862
First Posted: April 12, 2016
Last Update Posted: October 31, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cidara Therapeutics Inc.
March 16, 2016
April 12, 2016
October 31, 2017
July 26, 2016
October 2017   (Final data collection date for primary outcome measure)
  • Incidence of treatment emergent adverse events [safety and tolerability] [ Time Frame: Day 45- 52 for subjects with candidemia only or Day 52- 59 for subjects with invasive candidiasis with or without candidemia ]
    Number of subjects with treatment emergent adverse events, clinical chemistry, hematology, and urine analysis laboratory tests, vital signs, physical exams, and ECG abnormalities
  • Mycological eradication or presumed mycological eradication [ Time Frame: Day 14 (+/- 1 day) ]
    Number of subjects with negative blood culture(s) for yeast or Candida and no change of antifungal therapy for treatment of candidemia or number of subjects in whom no follow-up culture is available with no change of antifungal treatment for invasive candidiasis and resolution of or improvement of any baseline radiographic abnormalities due to invasive candidiasis
  • Resolution of systemic signs attributable to candidemia and/or invasive candidiasis [ Time Frame: Day 14 (+/- 1 day) ]
    Number of subjects with complete resolution of all systemic signs of candidemia and/or invasive candidiasis which were present at baseline
  • Incidence of treatment emergent adverse events [safety and tolerability] [ Time Frame: Day 28 - 35 ]
    Adverse events, clinical chemistry and hematology laboratory tests, vital signs, physical exams
  • Negative blood culture [ Time Frame: Day 14 ]
    Negative blood culture(s) for yeast [mycological eradication]
Complete list of historical versions of study NCT02734862 on ClinicalTrials.gov Archive Site
  • Mycological eradication or presumed mycological eradication [ Time Frame: Day 5 ]
    Number of subjects with negative blood culture(s) for yeast or Candida and no change of antifungal therapy for treatment of candidemia or number of subjects in whom no follow-up culture is available with no change of antifungal treatment for invasive candidiasis and resolution of or improvement of any baseline radiographic abnormalities due to invasive candidiasis
  • Resolution of systemic signs attributable to candidemia and/or invasive candidiasis [ Time Frame: Day 5 ]
    Subjects with no new clinical signs or symptoms attributable to candidemia and/or invasive candidiasis that were present at baseline
  • Survival [ Time Frame: Day 14 (+/- 1 day) ]
    Number of subjects alive
  • Mycological eradication or presumed mycological eradication [ Time Frame: Day 28 (+/- 2 days) for subjects with invasive candidiasis ]
    Number of subjects in whom no follow-up culture is available with no change of antifungal treatment for invasive candidiasis and resolution of or improvement of any baseline radiographic abnormalities due to invasive candidiasis
  • Resolution of systemic signs attributable to candidemia and/or invasive candidiasis [ Time Frame: Day 28 (+/- 2 days) for subjects with invasive candidiasis ]
    Number of subjects with complete resolution of all the systemic signs of candidemia and/or invasive candidiasis that were present at baseline
  • Survival [ Time Frame: Day 28 (+/- 2 days) for subjects with invasive candidiasis ]
    Number of subjects alive
  • Resolution of systemic signs attributable to candidemia and/or invasive candidiasis [ Time Frame: Day 45-52 for subjects with candidemia only or Day 52- 59 for subjects with invasive candidiasis with or without candidemia ]
    Number of subjects with complete resolution of all the systemic signs of candidemia which were present at baseline
  • Mycological eradication or presumed mycological eradication [ Time Frame: Day 45-52 for subjects with candidemia only or Day 52- 59 for subjects with invasive candidiasis with or without candidemia ]
    Number of subjects with negative blood culture(s) for yeast or Candida and no change of antifungal therapy for treatment of candidemia or number of subjects in whom no follow-up culture is available with no change of antifungal treatment for invasive candidiasis and resolution of or improvement of any baseline radiographic abnormalities due to invasive candidiasis
  • Survival [ Time Frame: Day 45-52 for subjects with candidemia only or Day 52- 59 for subjects with invasive candidiasis with or without candidemia ]
    Number of subjects alive
  • Negative blood culture [ Time Frame: Day 5 ]
    Negative blood culture(s) for yeast [mycological eradication]
  • Resolution of clinical signs and symptoms of candidemia [ Time Frame: Day 14 ]
    Complete resolution of most or all the clinical signs and symptoms of candidemia which were present at baseline AND no new signs/ symptoms or complications attributable to candidemia AND no additional antifungal therapy administered for candidemia AND the subject is alive [clinical cure]
  • Resolution of clinical signs and symptoms of candidemia [ Time Frame: Day 28 - 35 ]
    Complete resolution of most or all the clinical signs and symptoms of candidemia which were present at baseline AND no new signs/ symptoms or complications attributable to candidemia AND no additional antifungal therapy administered for candidemia AND the subject is alive [clinical cure]
  • Negative blood culture [ Time Frame: Day 28 - 35 ]
    Negative blood culture(s) for yeast [mycological eradication]
Not Provided
Not Provided
 
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis
A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Candidemia
  • Mycoses
  • Fungal Infection
  • Fungemia
  • Invasive Candidiasis
  • Drug: CD101
    Intravenous antifungal therapy
    Other Names:
    • CD101 Injection
    • CD101 for Injection
  • Drug: Caspofungin
    Intravenous antifungal therapy
    Other Name: Cancidas
  • Drug: Fluconazole
    oral antifungal therapy
    Other Name: generic fluconazole
  • Drug: intravenous placebo
    normal saline
    Other Name: placebo infusion
  • Drug: oral placebo
    microcrystalline cellulose
    Other Name: encapsulated cellulose
  • Experimental: Group 1

    Subjects in the CD101 IV treatment group 1 will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.

    Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down.

    Interventions:
    • Drug: CD101
    • Drug: intravenous placebo
    • Drug: oral placebo
  • Experimental: Group 2

    Subjects in the CD101 IV treatment group 2 will receive CD101 IV 400 mg on Day 1 and 200 mg on Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.

    Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as oral step down.

    Interventions:
    • Drug: CD101
    • Drug: intravenous placebo
    • Drug: oral placebo
  • Active Comparator: Group 3

    Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).

    After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.

    Interventions:
    • Drug: Caspofungin
    • Drug: Fluconazole
    • Drug: intravenous placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
114
November 2017
October 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • mycological diagnosis of candidemia and/or invasive candidiasis from a sample taken less than or equal to 96 hours before randomization (defined as: at least 1 blood culture positive for Candida or positive test for Candida from a sponsor approved rapid diagnostic test or positive gram stain for yeast or positive culture for Candida spp. from a specimen obtained from a normally sterile site)
  • willing to initiate or continue medical treatment to cure infections, including receipt of antibiotics and surgical procedures, if required. Patients receiving only medications and measures for comfort and not cure should not be enrolled.
  • female subjects of child bearing potential <2 years post menopausal must agree to one barrier method and one highly effective method of birth control or sexual abstinence.
  • male subjects must agree to use one barrier method of birth control or sexual abstinence
  • willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally acceptable representative must provide informed consent on their behalf.
  • presence of one or more systemic signs attributable to candidemia and/or invasive candidiasis

Exclusion Criteria:

  • Any of the following forms of IC:

    1. Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed)
    2. Osteomyelitis
    3. Endocarditis or myocarditis
    4. Meningitis, endophthalmitis, or any central nervous system infection
  • neutropenia
  • alanine aminotransferase or aspartate aminotransferase levels >10 fold the upper limit of normal
  • severe hepatic impairment in subjects with a history of chronic cirrhosis
  • greater than 48 hours systemic antifungal treatment at approved doses to treat candidemia
  • pregnant females
  • lactating females who are nursing
  • known hypersensitivity to CD101, caspofungin, any echinocandin, or to any of their excipients
  • previous participation in this or any previous CD101 study
  • recent use of an investigational medicinal product within 28 days of first dose of study drug or presence of an investigational device at the time of screening
  • Principal Investigator considers the subject should not participate
  • presence of indwelling vascular catheter or device that cannot be removed and is likely to be the source of candidemia
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Karen Mena (858) 888-7868 clinicaltrialinfo@cidara.com
Belgium,   Bulgaria,   Canada,   Greece,   Hungary,   Italy,   Russian Federation,   Spain,   United States
 
 
NCT02734862
CD101.IV.2.03
2015-005599-51 ( EudraCT Number )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Cidara Therapeutics Inc.
Cidara Therapeutics Inc.
Not Provided
Study Director: Taylor Sandison, MD MPH Cidara Therapeutics
Cidara Therapeutics Inc.
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP